FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2527706418> ?p ?o ?g. }

• W2527706418 abstract "Abstract AMLs constitute an heterogeneous group of hematopoietic stem cell disorders of rather poor prognosis. Abnormal activation of signaling pathways including STAT, MAPK and NF-KB have been described in AMLs and could constitute new targets for therapy. In this study, we focused on the PI3K/AKT and mTOR/P70S6K activity in primary blast cells purified from the bone marrow of patients with primary (n = 54) or secondary (n =10) AMLs. Patients with de novo AMLs were issued from the AML2001 French Multicenter Trial directed by the GOELAMS. The FAB classification was the following: M0 (n = 8), M1 (n = 10) M2 (n = 21), M4 (n = 10), M4eo (n = 2), M5 (n = 11), unknown AML (n = 2). In 58% of these patients, a constitutive activation of PI3K/AKT was detected in blast cells by western blot analysis showing AKT and FOXO3a phosphorylation, and confirmed by immunofluorescence confocal microscopy and flow cytometry analysis in CD34+ blast cells. Constitutive GAB1/2 phosphorylation was detected in all PI3K+ patients. However, we did not find any correlation between PI3K activation and FLT3 gene mutations. PTEN and SHIP-1 expression was normal in all tested PI3K+ patients. Proliferation (3H thymidine incorporation) was significantly increased in PI3K+ samples compared to PI3K- samples (p=0.001). The mTOR/P70S6K pathway was activated and the mTOR inhibitor rapamycin selectively reduced proliferation of PI3K+ samples. We determined the expression of the alpha, beta and delta isoforms of the catalytic sub-unit of PI3K (p110) in leukemic cells and found that p110 delta was the only consistently expressed isoform. In 8 PI3K+ samples tested, IC87114 (ICOS Corporation), a specific p110delta inhibitor compound used at 10μM totally suppressed AKT and FOXO3a phosphorylation. IC87114 inhibited proliferation of PI3K+ leukemic cells whereas it did not induce apoptosis. IC87114 did not significantly impaired the proliferation of PI3K- blast cells. Interestingly, IC87114 did not inhibit the proliferation or clonogenicity of CD34+ cord blood cells cultured in SCF, FLT3L and TPO used as controls. Overall, our results report, a/ a constitutive activation of PI3K in 58% of AML, b/ no correlation between FLT3 gene mutations and PI3K positivity, c/ no implication of PTEN or SHIP-1 phosphatases in PI3K activation, d/ a major role of the p110 delta isoform of PI3K in leukemic cell proliferation, e/ a potential therapeutic value of inhibiting mTOR and P110 delta activity." @default.
• W2527706418 created "2016-10-14" @default.
• W2527706418 creator A5001503693 @default.
• W2527706418 creator A5015832963 @default.
• W2527706418 creator A5018101860 @default.
• W2527706418 creator A5020454280 @default.
• W2527706418 creator A5023810956 @default.
• W2527706418 creator A5025108931 @default.
• W2527706418 creator A5026525163 @default.
• W2527706418 creator A5029880064 @default.
• W2527706418 creator A5031622487 @default.
• W2527706418 creator A5034948751 @default.
• W2527706418 creator A5035348501 @default.
• W2527706418 creator A5037324033 @default.
• W2527706418 creator A5040565591 @default.
• W2527706418 creator A5045374333 @default.
• W2527706418 creator A5045486644 @default.
• W2527706418 creator A5045839362 @default.
• W2527706418 creator A5051010078 @default.
• W2527706418 creator A5052222429 @default.
• W2527706418 creator A5070897866 @default.
• W2527706418 creator A5072173051 @default.
• W2527706418 creator A5080973292 @default.
• W2527706418 creator A5082764126 @default.
• W2527706418 creator A5085656105 @default.
• W2527706418 creator A5087324170 @default.
• W2527706418 creator A5087671059 @default.
• W2527706418 creator A5089287388 @default.
• W2527706418 creator A5089523733 @default.
• W2527706418 date "2004-11-16" @default.
• W2527706418 modified "2023-09-27" @default.
• W2527706418 title "Blockade of p110delta Isoform Activity of Phosphoinositide 3-Kinase Inhibits Blast Cell Proliferation in Acute Myeloblastic Leukemia." @default.
• W2527706418 doi "https://doi.org/10.1182/blood.v104.11.2522.2522" @default.
• W2527706418 hasPublicationYear "2004" @default.
• W2527706418 type Work @default.
• W2527706418 sameAs 2527706418 @default.
• W2527706418 citedByCount "2" @default.
• W2527706418 crossrefType "journal-article" @default.
• W2527706418 hasAuthorship W2527706418A5001503693 @default.
• W2527706418 hasAuthorship W2527706418A5015832963 @default.
• W2527706418 hasAuthorship W2527706418A5018101860 @default.
• W2527706418 hasAuthorship W2527706418A5020454280 @default.
• W2527706418 hasAuthorship W2527706418A5023810956 @default.
• W2527706418 hasAuthorship W2527706418A5025108931 @default.
• W2527706418 hasAuthorship W2527706418A5026525163 @default.
• W2527706418 hasAuthorship W2527706418A5029880064 @default.
• W2527706418 hasAuthorship W2527706418A5031622487 @default.
• W2527706418 hasAuthorship W2527706418A5034948751 @default.
• W2527706418 hasAuthorship W2527706418A5035348501 @default.
• W2527706418 hasAuthorship W2527706418A5037324033 @default.
• W2527706418 hasAuthorship W2527706418A5040565591 @default.
• W2527706418 hasAuthorship W2527706418A5045374333 @default.
• W2527706418 hasAuthorship W2527706418A5045486644 @default.
• W2527706418 hasAuthorship W2527706418A5045839362 @default.
• W2527706418 hasAuthorship W2527706418A5051010078 @default.
• W2527706418 hasAuthorship W2527706418A5052222429 @default.
• W2527706418 hasAuthorship W2527706418A5070897866 @default.
• W2527706418 hasAuthorship W2527706418A5072173051 @default.
• W2527706418 hasAuthorship W2527706418A5080973292 @default.
• W2527706418 hasAuthorship W2527706418A5082764126 @default.
• W2527706418 hasAuthorship W2527706418A5085656105 @default.
• W2527706418 hasAuthorship W2527706418A5087324170 @default.
• W2527706418 hasAuthorship W2527706418A5087671059 @default.
• W2527706418 hasAuthorship W2527706418A5089287388 @default.
• W2527706418 hasAuthorship W2527706418A5089523733 @default.
• W2527706418 hasConcept C11960822 @default.
• W2527706418 hasConcept C153911025 @default.
• W2527706418 hasConcept C2777609662 @default.
• W2527706418 hasConcept C2781322055 @default.
• W2527706418 hasConcept C43060935 @default.
• W2527706418 hasConcept C502942594 @default.
• W2527706418 hasConcept C55493867 @default.
• W2527706418 hasConcept C62112901 @default.
• W2527706418 hasConcept C62478195 @default.
• W2527706418 hasConcept C75217442 @default.
• W2527706418 hasConcept C86554907 @default.
• W2527706418 hasConcept C86803240 @default.
• W2527706418 hasConcept C95444343 @default.
• W2527706418 hasConceptScore W2527706418C11960822 @default.
• W2527706418 hasConceptScore W2527706418C153911025 @default.
• W2527706418 hasConceptScore W2527706418C2777609662 @default.
• W2527706418 hasConceptScore W2527706418C2781322055 @default.
• W2527706418 hasConceptScore W2527706418C43060935 @default.
• W2527706418 hasConceptScore W2527706418C502942594 @default.
• W2527706418 hasConceptScore W2527706418C55493867 @default.
• W2527706418 hasConceptScore W2527706418C62112901 @default.
• W2527706418 hasConceptScore W2527706418C62478195 @default.
• W2527706418 hasConceptScore W2527706418C75217442 @default.
• W2527706418 hasConceptScore W2527706418C86554907 @default.
• W2527706418 hasConceptScore W2527706418C86803240 @default.
• W2527706418 hasConceptScore W2527706418C95444343 @default.
• W2527706418 hasLocation W25277064181 @default.
• W2527706418 hasOpenAccess W2527706418 @default.
• W2527706418 hasPrimaryLocation W25277064181 @default.
• W2527706418 hasRelatedWork W1993312761 @default.
• W2527706418 hasRelatedWork W2000570054 @default.
• W2527706418 hasRelatedWork W2031968704 @default.
• W2527706418 hasRelatedWork W2219191688 @default.
• W2527706418 hasRelatedWork W2380028180 @default.
• W2527706418 hasRelatedWork W2754694451 @default.

• next